Evaluation of mRNA-1273 SARS-CoV-2 vaccine in adolescents
Open accessAbstract
BACKGROUND: The incidence of coronavirus disease 2019 (Covid-19) among adolescents between 12 and 17 years of age was approximately 900 per 100,000 population from April 1 through June 11, 2021. The safety, immunogenicity, and efficacy of the mRNA-1273 vaccine in adolescents are unknown. METHODS: In this ongoing phase 2-3, placebo-controlled trial, we randomly assigned healthy adolescents (12 to 17 years of age) in a 2:1 ratio to receive two injections of the mRNA-1273 vaccine (100 μg in each) or placebo, administered 28 days apart. The primary objectives were evaluation of the safety of mRNA-1273 in adolescents and the noninferiority of the immune response in adolescents as compared with that in young adults (18 to 25 years of age) in a phase 3 trial. Secondary objectives included the efficacy of mRNA-1273 in preventing Covid-19 or asymptomatic severe acute respiratory syndrome coronavirus 2 infection. RESULTS: A total of 3732 participants were randomly assigned to receive mRNA-1273 (2489 participants) or placebo (1243 participants). In the mRNA-1273 group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 93.1% and 92.4%, respectively), headache (in 44.6% and 70.2%, respectively), and fatigue (in 47.9% and 67.8%, respectively); in the placebo group, the most common solicited adverse reactions after the first or second injections were injection-site pain (in 34.8% or 30.3%, respectively), headache (in 38.5% and 30.2%, respectively), and fatigue (in 36.6% and 28.9%, respectively). No serious adverse events related to mRNA-1273 or placebo were noted. The geometric mean titer ratio of pseudovirus neutralizing antibody titers in adolescents relative to young adults was 1.08 (95% confidence interval [CI], 0.94 to 1.24), and the absolute difference in serologic response was 0.2 percentage points (95% CI, -1.8 to 2.4), which met the noninferiority criterion. No cases of Covid-19 with an onset of 14 days after the second injection were reported in the mRNA-1273 group, and four cases occurred in the placebo group. CONCLUSIONS: The mRNA-1273 vaccine had an acceptable safety profile in adolescents. The immune response was similar to that in young adults, and the vaccine was efficacious in preventing Covid-19. (Funded by Moderna and the Biomedical Advanced Research and Development Authority; Teen COVE ClinicalTrials.gov number, NCT04649151.).
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
mRNA-1273 showed 94.1% efficacy at preventing COVID-19 illness, including severe disease, in participants 18 years or older and 95% efficacy in 12- to 17-year-olds.
“94.1% efficacy at preventing COVID-19 illness, including severe disease in participants 18 years or older995% efficacy in 12- to 17-year olds84”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [84]
Similar immune responses were observed among adolescents aged 12 to 17 after mRNA-1273.
“with similar immune responses among adolescents aged 12 to 17.410,412–414”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [412]
In a phase III clinical trial involving 30,420 people aged 18 or older, two doses of 100 μg mRNA-1273 with a 28-day interval had vaccine efficacy of 94.1%.
“In a phase III clinical trial involving 30,420 people, participants aged 18 or older were given two doses of 100 μg of mRNA-1273 with a 28-day interval, and vaccine efficacy was 94.1% (Table 5)”
From Advances in COVID-19 mRNA vaccine development (2022) · cites this paper as [412]
In 12- to 17-year-olds, mRNA-1273 showed 95% vaccine efficacy and had an acceptable safety profile.
“In 12- to 17-year-olds, mRNA-1273 showed 95% vaccine efficacy and had an acceptable safety profile.84”
From COVID-19 mRNA vaccines: Platforms and current developments (2022) · cites this paper as [84]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
Self-citationAn mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237 · see citing works
RNA-Based COVID-19 Vaccine BNT162b2 Selected for a Pivotal Efficacy Study
Walsh, E. E., Frenck, R., Falsey, A. R., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Neuzil, K., Mulligan, M. J., Bailey, R., et al. (2020) · doi:10.1101/2020.08.17.20176651 · Cited by 2,615 · see citing works
Age-dependent effects in the transmission and control of COVID-19 epidemics
Davies, N. G., Klepac, P., Liu, Y., Prem, K., Jit, M., CMMID COVID-19 working group, Pearson, C. A. B., Quilty, B. J., Kucharski, A. J., Gibbs, H. P., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0962-9 · Cited by 1,721 · see citing works
Safety and Immunogenicity of SARS-CoV-2 mRNA-1273 Vaccine in Older Adults
Anderson, E. J., Rouphael, N. G., Widge, A. T., Jackson, L. A., Roberts, P. C., Makhene, M., Chappell, J. D., Denison, M. R., Stevens, L. J., Pruijssers, A. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2028436 · Cited by 1,523 · see citing works
Self-citationFamily violence and COVID‐19: Increased vulnerability and reduced options for support
Usher, K., Bhullar, N., Durkin, J., Gyamfi, N., & Jackson, D. (2020) · International Journal of Mental Health Nursing · doi:10.1111/inm.12735 · Cited by 979 · see citing works
Safety, immunogenicity, and efficacy of the BNT162b2 covid-19 vaccine in adolescents
Frenck, R. W., Klein, N. P., Kitchin, N., Gurtman, A., Absalon, J., Lockhart, S., Perez, J. L., Walter, E. B., Senders, S., Bailey, R., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107456 · Cited by 889 · see citing works
Susceptibility to SARS-CoV-2 Infection Among Children and Adolescents Compared With Adults
Viner, R., Mytton, O. T., Bonell, C. P., Meléndez‐Torres, G. J., Ward, J., Hudson, L. D., Waddington, C. S., Thomas, J., Russell, S., van der Klis, F. R. M., et al. (2020) · Archives of Pediatrics and Adolescent Medicine · doi:10.1001/jamapediatrics.2020.4573 · Cited by 838 · see citing works
Antibody Persistence through 6 Months after the Second Dose of mRNA-1273 Vaccine for Covid-19
Doria-Rose, N., Suthar, M. S., Makowski, M., O’Connell, S., McDermott, A. B., Flach, B., Ledgerwood, J. E., Mascola, J. R., Graham, B. S., Lin, B. C., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103916 · Cited by 673 · see citing works
Self-citationKim, L., WHITAKER, M. D., O’Halloran, A. C., Kambhampati, A. K., Chai, S. J., Reingold, A. L., Armistead, I., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6932e3 · Cited by 513 · see citing works
Age groups that sustain resurging COVID-19 epidemics in the United States
Monod, M., Blenkinsop, A., Xi, X., Hebert, D. J., Bershan, S., Tietze, S., Baguelin, M., Bradley, V. C., Chen, Y., Coupland, H., et al. (2021) · Science · doi:10.1126/science.abe8372 · Cited by 326 · see citing works
Suffering in silence: How COVID-19 school closures inhibit the reporting of child maltreatment
Baron, E. J., Goldstein, E. G., & Wallace, C. T. (2020) · Journal of Public Economics · doi:10.1016/j.jpubeco.2020.104258 · Cited by 316 · see citing works
Chu, L., McPhee, R. A., Huang, W., Bennett, H., Pajón, R., Nestorova, B., & Leav, B. A. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.02.007 · Cited by 225 · see citing works
Self-citationIncidence and secondary transmission of SARS-CoV-2 infections in schools
Zimmerman, K. O., Akinboyo, I. C., Brookhart, M. A., Boutzoukas, A. E., McGann, K. A., Smith, M. J., Maradiaga Panayotti, G., Armstrong, S. C., Bristow, H., Parker, D., et al. (2021) · Pediatrics · doi:10.1542/peds.2020-048090 · Cited by 223 · see citing works
Penner, J., Abdel‐Mannan, O., Grant, K., Maillard, S., Kučera, F., Hassell, J. K., Eyre, M., Berger, Z. E., Hacohen, Y., Moshal, K. L., et al. (2021) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(21)00138-3 · Cited by 205 · see citing works
Swedo, E. A., Idaikkadar, N., Leemis, R. W., Dias, T. P., Radhakrishnan, L., Stein, Z., Chen, M. W., Agathis, N. T., & Holland, K. M. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6949a1 · Cited by 170 · see citing works
FDA approves the Pfizer-BioNTech COVID-19 vaccine
Satyanarayana, M. (2021) · Chemical & Engineering News · doi:10.47287/cen-09931-buscon1 · Cited by 129 · see citing works
Havers, F. P., WHITAKER, M. D., Self, J. L., Chai, S. J., Kirley, P. D., Alden, N. B., Kawasaki, B., Meek, J. I., Yousey-Hindes, K. M., Anderson, E. J., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm7023e1 · Cited by 110 · see citing works
Hobbs, C. V., Martin, L., Kim, S. S., Kirmse, B., Haynie, L., McGraw, S., Byers, P., Taylor, K. G., Patel, M. M., Flannery, B. L., et al. (2020) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6950e3 · Cited by 84 · see citing works
Chua, G. T., Wong, J. S. C., Lam, I. C. S., Ho, P. K., Chan, W. H., Yau, F. Y. S., Duque, J. S. R., Ho, A. C. C., Siu, K. K., Cheung, T. W. Y., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2021.8824 · Cited by 64 · see citing works
Flagged first, then by citations
Research works printed but not linked: 1
- [26]Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and immunogenicity of two RNA-based Covid-19 vaccine candidates. N Engl J Med 2020; 383: 2439- 2450. 33053279 PMC7583697
Cited by
Sorted by citations
Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase
El Sahly, H. M., Baden, L. R., Essink, B., Doblecki-Lewis, S., Martin, J. M., Anderson, E. J., Campbell, T. B., Clark, J., Jackson, L. A., Fichtenbaum, C. J., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2113017 · Cited by 641 · see citing works
Self-citationAdvances in COVID-19 mRNA vaccine development
Fang, E., Liu, X., Li, M., Zhang, Z., Song, L., Zhu, B., Wu, X., Liu, J., Zhao, D., & Li, Y. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-00950-y · Cited by 601 · see citing works
Efficacy and safety of COVID-19 vaccines
Graña, C., Ghosn, L., Evrenoglou, T., Jarde, A., Minozzi, S., Bergman, H., Buckley, B. S., Probyn, K., Villanueva, G., Henschke, N., et al. (2022) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015477 · Cited by 310 · see citing works
COVID-19 mRNA vaccines: Platforms and current developments
Szabó, G. T., Mahiny, A. J., & Vlatkovic, I. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.02.016 · Cited by 308 · see citing works
Ssentongo, P., Ssentongo, A. E., Voleti, N., Groff, D., Sun, A., Ba, D. M., Nunez, J., Parent, L. J., Chinchilli, V. M., & Paules, C. I. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07418-y · Cited by 260 · see citing works
Ghattas, M., Dwivedi, G., Lavertu, M., & Alameh, M. (2021) · Vaccines · doi:10.3390/vaccines9121490 · Cited by 266 · see citing works
Chi, W.-Y., Li, Y.-D., Huang, H., Chan, T. E. H., Chow, S.-Y., Su, J.-H., Ferrall, L., Hung, C., & Wu, T. ‐. (2022) · Journal of Biomedical Science · doi:10.1186/s12929-022-00853-8 · Cited by 216 · see citing works
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Peterson, C., Lee, B., & Nugent, K. (2022) · Vaccines · doi:10.3390/vaccines10060948 · Cited by 194 · see citing works
Chemically Modified Platforms for Better RNA Therapeutics
Shi, Y., Zhen, X., Zhang, Y., Li, Y., Koo, S., Saiding, Q., Kong, N., Liu, G., Chen, W., & Tao, W. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00611 · Cited by 184 · see citing works
Evaluation of mRNA-1273 Covid-19 Vaccine in Children 6 to 11 Years of Age
Creech, C. B., Anderson, E. J., Berthaud, V., Yildirim, I. B., Atz, A. M., Baez, I. M., Finkelstein, D., Pickrell, P., Kirstein, J., Yut, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2203315 · Cited by 174 · see citing works
Self-citationHeidecker, B., Dagan, N., Balicer, R., Eriksson, U., Rosano, G., Coats, A., Tschöpe, C., Kelle, S., Poland, G. A., Frustaci, A., et al. (2022) · European Journal of Heart Failure · doi:10.1002/ejhf.2669 · Cited by 159 · see citing works
Au, W. Y., & Cheung, P. P.-H. (2022) · BMJ · doi:10.1136/bmj-2022-069989 · Cited by 143 · see citing works
Evaluation of mRNA-1273 Vaccine in Children 6 Months to 5 Years of Age
Anderson, E. J., Creech, C. B., Berthaud, V., Piramzadian, A., Johnson, K. A., Zervos, M., Garner, F., Griffin, C., Palanpurwala, K., Turner, M. A., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2209367 · Cited by 140 · see citing works
Self-citationYang, Z.-R., Jiang, Y.-W., Li, F.-X., Liu, D., Lin, T.-F., Zhao, Z.-Y., Wei, C., Jin, Q.-Y., Li, X.-M., Jia, Y.-X., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00390-1 · Cited by 138 · see citing works
Should children be vaccinated against COVID-19?
Zimmermann, P., Pittet, L. F., Finn, A. H. R., Pollard, A. J., & Curtis, N. C. (2021) · Archives of Disease in Childhood · doi:10.1136/archdischild-2021-323040 · Cited by 125 · see citing works
High Rate of Asymptomatic Carriage Associated with Variant Strain OmicronPreprint
Garrett, N., Tapley, A., Andriesen, J. G., Seocharan, I., Fisher, L. H., Bunts, L., Espy, N., Wallis, C. L., Randhawa, A. K., Ketter, N., et al. (2021) · medRxiv · doi:10.1101/2021.12.20.21268130 · Cited by 125 · see citing works
Polymer-Based Nanofiber–Nanoparticle Hybrids and Their Medical Applications
Zhang, M., Song, W., Tang, Y., Xu, X., Huang, Y., & Yu, D. (2022) · Polymers · doi:10.3390/polym14020351 · Cited by 124 · see citing works
Zabidi, N. Z., Liew, H. L., Farouk, I. A., Puniyamurti, A., Yip, A. J. W., Wijesinghe, V. N., Low, Z. Y., Tang, J. W.-T., Chow, V. T. K., & Lal, S. K. (2023) · Viruses · doi:10.3390/v15040944 · Cited by 121 · see citing works
Chu, L., Montefiori, D., Huang, W., Nestorova, B., Chang, Y., Carfi, A., Edwards, D. K., Oestreicher, J., Legault, H., Girard, B., et al. (2021) · doi:10.1101/2021.09.29.21264089 · Cited by 105 · see citing works
Self-citationGlobal acceptance and hesitancy of COVID-19 vaccination: A narrative review
Hassan, W., Kazmi, S. K., Tahir, M. J., Ullah, I., Royan, H. A., Fahriani, M., Nainu, F., & Viveiros-Rosa, S. G. (2021) · Narra J · doi:10.52225/narra.v1i3.57 · Cited by 98 · see citing works
Myocarditis in SARS-CoV-2 infection vs. COVID-19 vaccination: A systematic review and meta-analysis
Voleti, N., Reddy, S. P., & Ssentongo, P. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.951314 · Cited by 96 · see citing works
Personalized pancreatic cancer therapy: from the perspective of mRNA vaccine
Huang, X., Zhang, G., Tang, T., Gao, X., & Liang, T. (2022) · Military Medical Research · doi:10.1186/s40779-022-00416-w · Cited by 95 · see citing works
RNA chemistry and therapeutics
Wang, S., Weissman, D., & Dong, Y. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01237-x · Cited by 98 · see citing works
Development of mRNA vaccines against respiratory syncytial virus (RSV)
Qiu, X., Xu, S., Lu, Y., Luo, Z., Yan, Y., Wang, C., & Ji, J. (2022) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2022.10.001 · Cited by 83 · see citing works
mRNA Vaccines against SARS-CoV-2: Advantages and Caveats
Echaide, M., Chocarro, L., Bocanegra, A., Blanco, E., Kochan, G. T., & Escors, D. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065944 · Cited by 82 · see citing works
Tracking the COVID-19 vaccines: The global landscape
Yadav, T., Kumar, S., Mishra, G., & Saxena, S. K. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2191577 · Cited by 76 · see citing works
Effectiveness of BNT162b2 against COVID-19 in adolescents
Powell, A. A., Kirsebom, F., Stowe, J., McOwat, K., Saliba, V., Ramsay, M. E., Lopez-Bernal, J., Andrews, N., & Ladhani, S. N. (2022) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(22)00177-3 · Cited by 69 · see citing works
High Asymptomatic Carriage With the Omicron Variant in South Africa
Garrett, N., Tapley, A., Andriesen, J. G., Seocharan, I., Fisher, L. H., Bunts, L., Espy, N., Wallis, C. L., Randhawa, A. K., Miner, M. D., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac237 · Cited by 73 · see citing works
Morello, W., Vianello, F. A., Proverbio, E., Peruzzi, L., Pasini, A., & Montini, G. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05330-2 · Cited by 72 · see citing works
Glatman-Freedman, A., Hershkovitz, Y., Kaufman, Z., Dichtiar, R., Keinan-Boker, L., & Bromberg, M. (2021) · Emerging Infectious Diseases · doi:10.3201/eid2711.211886 · Cited by 70 · see citing works
Tian, F., Yang, R., & Chen, Z. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27940 · Cited by 67 · see citing works
SARS-CoV-2 infection in children and implications for vaccination
Nathanielsz, J., Toh, Z. Q., Do, L. A. H., Mulholland, K., & Licciardi, P. V. (2022) · Pediatric Research · doi:10.1038/s41390-022-02254-x · Cited by 64 · see citing works
The paradigm shift in treatment from Covid-19 to oncology with mRNA vaccines
Wei, J., & Hui, A.-M. (2022) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2022.102405 · Cited by 57 · see citing works
Messenger RNA vaccines for cancer immunotherapy: progress promotes promise
Huff, A. L., Jaffee, E. M., & Zaidi, N. (2022) · Journal of Clinical Investigation · doi:10.1172/jci156211 · Cited by 56 · see citing works
Dorabawila, V., Hoefer, D., Bauer, U. E., Bassett, M. T., Lutterloh, E. C., & Rosenberg, E. S. (2022) · medRxiv · doi:10.1101/2022.02.25.22271454 · Cited by 55 · see citing works
Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
Áñez, G., Dunkle, L. M., Gay, C. L., Kotloff, K. L., Adelglass, J. M., Essink, B. J., Campbell, J. D., Cloney-Clark, S., Zhu, M., Plested, J. S., et al. (2023) · JAMA Network Open · doi:10.1001/jamanetworkopen.2023.9135 · Cited by 52 · see citing works
Almalki, O. S., Alfayez, O. M., Yami, M. S. A., Asiri, Y. A., & Almohammed, O. A. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.842862 · Cited by 50 · see citing works
Pneumococcal Vaccines: Past Findings, Present Work, and Future Strategies
Oliveira, G. S., Oliveira, M. L. S., Miyaji, E. N., & Rodrigues, T. C. (2021) · Vaccines · doi:10.3390/vaccines9111338 · Cited by 49 · see citing works
Kildegaard, H., Lund, L. C., Højlund, M., Stensballe, L. G., & Pottegård, A. (2022) · BMJ · doi:10.1136/bmj-2021-068898 · Cited by 49 · see citing works
Yenew, C., Dessie, A. M., Gebeyehu, A. A., & Yeshiwas, A. G. (2023) · Human Vaccines & Immunotherapeutics · doi:10.1080/21645515.2023.2207442 · Cited by 54 · see citing works
Human type I IFN deficiency does not impair B cell response to SARS-CoV-2 mRNA vaccination
Sokal, A., Bastard, P., Chappert, P., Spaeth, G. B., Fourati, S., Vandenberghe, A., Lagouge-Roussey, P., Meyts, I., Gervais, A., Bouvier‐Alias, M., et al. (2022) · The Journal of Experimental Medicine · doi:10.1084/jem.20220258 · Cited by 48 · see citing works
Alimoradi, Z., Lin, C., & Pakpour, A. H. (2023) · Vaccines · doi:10.3390/vaccines11030533 · Cited by 47 · see citing works
Desmecht, S., Tashkeev, A., Moussaoui, M. E., Maréchal, N., Perée, H., Tokunaga, Y., Fombellida-Lopez, C., Polese, B., Legrand, C., Wéry, M., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.863554 · Cited by 45 · see citing works
Lutrick, K., Rivers, P. S., Yoo, Y. M., Grant, L., Hollister, J., Jovel, K. S., Khan, S. R., Lowe, A. A., Baccam, Z., Hanson, H., et al. (2021) · MMWR Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm705152a2 · Cited by 39 · see citing works
Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis
Sutton, N., Ramos, A. S. F., Beales, E. R., Smith, D., Ikram, S., Galiza, E. P., Hsia, Y., & Heath, P. T. (2022) · Expert Review of Vaccines · doi:10.1080/14760584.2022.2098719 · Cited by 42 · see citing works
SARS-CoV-2 mRNA vaccination elicits robust antibody responses in children
Bartsch, Y. C., Denis, K. S., Kapłonek, P., Kang, J., Lam, E. C., Burns, M. D., Farkas, E. J., Davis, J. P., Boribong, B. P., Edlow, A. G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abn9237 · Cited by 56 · see citing works
Analysis of Myocarditis Among 252 Million mRNA-1273 Recipients Worldwide
Straus, W., Urdaneta, V., Esposito, D. B., Mansi, J. A., Sanz Rodriguez, C., Burton, P., & Vega, J. M. (2023) · Clinical Infectious Diseases · doi:10.1093/cid/ciac446 · Cited by 41 · see citing works
A comprehensive analysis of the efficacy and effectiveness of COVID-19 vaccines
He, X., Su, J., Ma, Y., Zhang, W., & Tang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.945930 · Cited by 40 · see citing works
Lipid Nanoparticles for mRNA Delivery to Enhance Cancer Immunotherapy
Wang, H., Wang, Z.-G., & Liu, S. (2022) · Molecules · doi:10.3390/molecules27175607 · Cited by 40 · see citing works
Sadeghi, S., Kalantari, Y., Shokri, S., Fallahpour, M., Nafissi, N., Goodarzi, A., & Valizadeh, R. (2022) · Journal of Clinical Virology · doi:10.1016/j.jcv.2022.105196 · Cited by 39 · see citing works
Du, Y., Chen, L., & Shi, Y. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.829176 · Cited by 39 · see citing works
mRNA-Based Vaccine for COVID-19: They Are New but Not Unknown!
Chavda, V. P., Jogi, G., Dave, S., Patel, B. M., Nalla, L. V., & Koradia, K. D. (2023) · Vaccines · doi:10.3390/vaccines11030507 · Cited by 38 · see citing works
Safety outcomes following COVID-19 vaccination and infection in 5.1 million children in England
Copland, E., Patone, M., Saatci, D., Handunnetthi, L., Hirst, J. A., Hunt, D. P. J., Mills, N. L., Moss, P. A. H., Sheikh, A., Coupland, C. A. C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-47745-z · Cited by 38 · see citing works
Chalkias, S., Dennis, P., Petersen, D., Radhakrishnan, K., Vaughan, L. B., Handforth, R., Rossi, A., Wahid, R., Edwards, D. K., Feng, J., et al. (2025) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(25)00236-1 · Cited by 38 · see citing works
Self-citationBaden, L. R., Sahly, H. M. E., Essink, B. J., Follmann, D. A., Hachigian, G., Strout, C. B., Overcash, J. S., Doblecki‐Lewis, S., Whitaker, J. A., Anderson, E. J., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50376-z · Cited by 37 · see citing works
Self-citationmRNA vaccines against respiratory viruses
Whitaker, J. A., Sahly, H. M. E., & Healy, C. M. (2023) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000948 · Cited by 38 · see citing works
González, S. E., Olszevicki, S., Gaiano, A., Baino, A. N. V., Regairaz, L., Salazar, M. R., Pesci, S. A., Marín, L., González, V., Varela, T., et al. (2022) · The Lancet Regional Health - Americas · doi:10.1016/j.lana.2022.100316 · Cited by 34 · see citing works
Thuluva, S., Paradkar, V. M., Gunneri, S., Yerroju, V., Mogulla, R. R., Suneetha, P. V., Turaga, K., Kyasani, M., Manoharan, S. K., Adabala, S., et al. (2022) · Vaccine · doi:10.1016/j.vaccine.2022.10.045 · Cited by 33 · see citing works
Zhang, G. F., Meng, W., Chen, L., Ding, L., Feng, J., Pérez, J., Ali, A., Sun, S., Liu, Z., Huang, Y., et al. (2022) · Journal of Medical Virology · doi:10.1002/jmv.28032 · Cited by 36 · see citing works
Mutational dynamics of SARS-CoV-2: Impact on future COVID-19 vaccine strategies
Faraji, N., Zeinali, T., Joukar, F., Aleali, M. S., Eslami, N., Shenagari, M., & Mansour‐Ghanaei, F. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e30208 · Cited by 31 · see citing works
mRNA vaccines in tumor targeted therapy: mechanism, clinical application, and development trends
Gao, Y., Yang, L., Li, Z., Peng, X., & Li, H. (2024) · Biomarker Research · doi:10.1186/s40364-024-00644-3 · Cited by 33 · see citing works
COVID-19-Vaccination-Induced Myocarditis in Teenagers: Case Series with Further Follow-Up
Puchalski, M., Kamińska, H., Bartoszek, M., Brzewski, M., & Werner, B. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19063456 · Cited by 32 · see citing works
Xu, K., Fan, C., Han, Y., Dai, L., & Gao, G. F. (2022) · International Immunology · doi:10.1093/intimm/dxac031 · Cited by 31 · see citing works
Safety and efficacy of the COVID-19 vaccine in children and/or adolescents:A meta-analysis
Xu, W., Tang, J., Chen, C., Wang, C., Wen, W., Cheng, Y., Zhou, M., Wu, Q., Zhang, X., Feng, Z., et al. (2022) · Journal of Infection · doi:10.1016/j.jinf.2022.01.032 · Cited by 31 · see citing works
Emerging and re-emerging pediatric viral diseases: a continuing global challenge
Hoffman, S. A., & Maldonado, Y. (2023) · Pediatric Research · doi:10.1038/s41390-023-02878-7 · Cited by 33 · see citing works
Qin, C., Wang, R., Tao, L., Liu, M., & Liu, J. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.834572 · Cited by 32 · see citing works
Challenges of vaccination and herd immunity in COVID‐19 and management strategies
She, J., Hou, D., Chen, C., Bi, J., & Song, Y. (2022) · The Clinical Respiratory Journal · doi:10.1111/crj.13543 · Cited by 28 · see citing works
Gao, P., Cai, S., Liu, Q., Du, M., Liu, J., & Liu, M. (2022) · Vaccines · doi:10.3390/vaccines10030421 · Cited by 26 · see citing works
Gao, P., Kang, L., Liu, J., & Liu, M. (2023) · World Journal of Pediatrics · doi:10.1007/s12519-022-00680-9 · Cited by 26 · see citing works
An MPXV mRNA-LNP vaccine candidate elicits protective immune responses against monkeypox virus
Tian, Y., Li, M., Yang, Y., Li, C., Peng, Y., Yang, H., Zhao, M., Wu, P., Ruan, S., Huang, Y., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.109270 · Cited by 26 · see citing works
Clinical advancements in mRNA vaccines against viral infections
Fatima, M. T., Park, P., & Hong, K. (2024) · Clinical Immunology · doi:10.1016/j.clim.2024.110424 · Cited by 25 · see citing works
Shiri, T., Evans, M., Talarico, C. A., Morgan, A. R., Mussad, M., Buck, P. O., McEwan, P. C., & Strain, W. D. (2021) · Vaccines · doi:10.3390/vaccines9101180 · Cited by 25 · see citing works
Rudan, I., Adeloye, D., Katikireddi, S. V., Murray, J., Simpson, C. R., Shah, S. A., Robertson, C., & Sheikh, A. (2021) · Journal of Global Health · doi:10.7189/jogh.11.01011 · Cited by 24 · see citing works
Inactivated Vaccine-Induced SARS-CoV-2 Variant-Specific Immunity in Children
Soto, J. A., Melo-González, F., Gutiérrez-Vera, C., Schultz, B. M., Berríos-Rojas, R. V., Rivera-Pérez, D., Piña-Iturbe, A., Hoppe-Elsholz, G., Duarte, L. F., Vázquez, Y., et al. (2022) · mBio · doi:10.1128/mbio.01311-22 · Cited by 25 · see citing works
Jutel, M., Torres, M. J., Palomares, Ó., Akdiş, C. A., Eiwegger, T., Untersmayr, E., Barber, D., Zemelka‐Wiącek, M., Kosowska, A., Palmer, E. N., et al. (2022) · Allergy · doi:10.1111/all.15252 · Cited by 24 · see citing works
Copaescu, A. M., Duque, J. S. R., & Phillips, E. J. (2022) · Annals of Allergy Asthma & Immunology · doi:10.1016/j.anai.2022.03.030 · Cited by 24 · see citing works
Veneti, L., Berild, J. D., Watle, S. V., Starrfelt, J., Greve‐Isdahl, M., Langlete, P., Bøås, H., Bragstad, K., Hungnes, O., & Meijerink, H. (2023) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2023.03.004 · Cited by 24 · see citing works
Comparative efficacy and safety of COVID-19 vaccines in phase III trials: a network meta-analysis
Wu, X., Xu, K., Zhan, P., Liu, H., Zhang, F., Song, Y., & Lv, T. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-023-08754-3 · Cited by 24 · see citing works
Immune Evasive Effects of SARS-CoV-2 Variants to COVID-19 Emergency Used Vaccines
Zhang, Y., Ndzouboukou, J. B., Gan, M., Lin, X., & Fan, X. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.771242 · Cited by 21 · see citing works
Reynolds, L., Dewey, C. E., Asfour, G., & Little, M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1229716 · Cited by 24 · see citing works
mRNA-1273 Vaccine-elicited Neutralization of SARS-CoV-2 Omicron in Adolescents and Children
Girard, B., Tomassini, J. E., Deng, W., Maglinao, M., Zhou, H., Figueroa, A., Ghamloush, S. S., Montefiori, D. C., Das, R., & Pajon, R. (2022) · doi:10.1101/2022.01.24.22269666 · Cited by 23 · see citing works
Self-citationGao, L., Li, Y., He, P., Chen, Z., Yang, H., Li, F., Zhang, S., Wang, D., Wang, G., Yang, S., et al. (2023) · The Lancet Child & Adolescent Health · doi:10.1016/s2352-4642(22)00376-5 · Cited by 22 · see citing works
Development of COVID-19 vaccine policy — United States, 2020–2023
Oliver, S. E., Wallace, M. M., Twentyman, E., Moulia, D., Godfrey, M., Link‐Gelles, R., Meyer, S. A., Fleming-Dutra, K. E., Hall, E., Wolicki, J., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.12.022 · Cited by 23 · see citing works
Xia, S., Duan, K., Zhang, Y., Zeng, X., Zhao, D., Zhang, H., Xie, Z., Li, X., Peng, C., Zhang, W. J., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.898151 · Cited by 21 · see citing works
Yeo, J. G., Chia, W. N., Teh, K. L., Book, Y. X., Hoh, S. F., Gao, X., Das, L., Zhang, J., Sutamam, N. B., Lim, A. J. M., et al. (2022) · Rheumatology · doi:10.1093/rheumatology/keac105 · Cited by 21 · see citing works
Seery, V., Raiden, S., Russo, C., Borda, M., Herrera, L., Uranga, M., Varese, A., del Pont, M. M., Chirino, C., Erramuspe, C., et al. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104230 · Cited by 19 · see citing works
The Potential of Nanomedicine to Unlock the Limitless Applications of mRNA
Taina-González, L., & de la Fuente, M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14020460 · Cited by 21 · see citing works
Humoral Immunogenicity of the mRNA-1273 Vaccine in the Phase 3 Coronavirus Efficacy (COVE) Trial
Sahly, H. M. E., Baden, L. R., Essink, B. J., Montefiori, D. C., McDermont, A., Rupp, R. E., Lewis, M., Swaminathan, S., Griffin, C., Fragoso, V. G., et al. (2022) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiac188 · Cited by 21 · see citing works
Self-citationPuga-Gómez, R., Ricardo-Delgado, Y., Iriarte, C. R., Céspedes-Henriquez, L., Piedra-Bello, M., Mendoza, D. L. V., Pérez, N. P., Paredes-Moreno, B., Rodríguez-González, M., Valenzuela‐Silva, C., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.11.016 · Cited by 20 · see citing works
Reflexões sobre o uso das vacinas para COVID-19 em crianças e adolescentes
Lima, E. J. D. F., de Faria, S. M., & Kfouri, R. D. Á. (2021) · Epidemiologia e Serviços de Saúde · doi:10.1590/s1679-49742021000400028 · Cited by 19 · see citing works
Sobczak, M., & Pawliczak, R. (2022) · Annals of Clinical Microbiology and Antimicrobials · doi:10.1186/s12941-022-00525-3 · Cited by 19 · see citing works
Guidelines for the prevention and management of children and adolescents with COVID-19
Liu, E., Smyth, R. L., Li, Q., Qaseem, A., Flórez, I. D., Mathew, J., Amer, Y. S., Estill, J., Fu, Z., Lü, X., et al. (2022) · European Journal of Pediatrics · doi:10.1007/s00431-022-04615-4 · Cited by 19 · see citing works
Cinicola, B. L., Mortari, E. P., Zicari, A. M., Agrati, C., Bordoni, V., Albano, C., Fedele, G., Schiavoni, I., Leone, P., Fiore, S., et al. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1094727 · Cited by 19 · see citing works
Veneti, L., Berild, J. D., Watle, S. V., Starrfelt, J., Greve‐Isdahl, M., Langlete, P., Bøås, H., Bragstad, K., Hungnes, O., & Meijerink, H. (2022) · medRxiv · doi:10.1101/2022.03.24.22272854 · Cited by 19 · see citing works
Chung, W., Preclaro, I. A. C., Chung, W., & Wang, C. (2022) · Biomedicines · doi:10.3390/biomedicines10061260 · Cited by 18 · see citing works
A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants
Rabaan, A. A., Mutair, A. S. A., Hajissa, K., Alfaraj, A. H., Al-Jishi, J. M., Alhajri, M. M., Alwarthan, S. M., Alsuliman, S. A., Al-Najjar, A. H., Al-Zaydani, I. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10101655 · Cited by 18 · see citing works
Krakowczyk, J. B., Bäuerle, A., Pape, L., Kaup, T., Nulle, L., Teufel, M., & Skoda, E. (2022) · Vaccines · doi:10.3390/vaccines10071155 · Cited by 18 · see citing works
The current status of COVID-19 vaccines. A scoping review
Rueda-Fernández, M., Melguizo‐Rodríguez, L., Costela-Ruiz, V. J., González‐Acedo, A., Ramos‐Torrecillas, J., & Montes, R. I. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.08.004 · Cited by 19 · see citing works
Ethics of age de-escalation in pediatric vaccine trials: Attending to the case of COVID-19
Harbin, A., Laventhal, N. T., & Navin, M. C. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.01.055 · Cited by 17 · see citing works
COVID-19 in children and the importance of COVID-19 vaccination
Xue, F.-X., & Shen, K. (2021) · World Journal of Pediatrics · doi:10.1007/s12519-021-00466-5 · Cited by 16 · see citing works
- Authors
- Ali, K., Berman, G., Zhou, H., Deng, W., Faughnan, V., Coronado-Voges, M., Ding, B., Dooley, J., Girard, B., Hillebrand, W., Pajon, R., Miller, J. M., Leav, B., & McPhee, R.
- Affiliations
- From Kool Kids Pediatrics, DM Clinical Research, Houston (K.A.); the Clinical Research Institute, Minneapolis (G.B.); and Moderna, Cambridge, MA (H.Z., W.D., V.F., M.C.-V., B.D., J.D., B.G., W.H., R.P., J.M.M., B.L., R.M.).
- Corresponding author
- McPhee, Roderick
- ORCID
- Girard, Bethany
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-12-09
- Volume
- 385
- Issue
- 24
- Pages
- 2241-2251
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8385554
- OpenAlex
- W3189261358
- Cited by
- 377
- References
- 20
- Citations by year
- 2026: 12 · 2025: 29 · 2024: 54 · 2023: 87 · 2022: 160 · 2021: 35
- FWCI
- 26.58
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- mRNA-1273 vaccine, SARS-CoV-2, COVID-19 vaccines, adolescents, vaccine safety, immunogenicity, neutralizing antibodies, non-inferiority, vaccine efficacy, asymptomatic infection, adverse events, serological response, pseudovirus neutralization assay, Omicron variant, Omicron BA.1
- MeSH terms
- Immunogenicity, Vaccine, COVID-19, Vaccine Efficacy, 2019-nCoV Vaccine mRNA-1273, Adolescent, Antibodies, Viral, Child, Female, Humans, Male, Single-Blind Method, Antibodies, Neutralizing
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
